Hemophilia B patient Pete Dyson at home with his young sons

Helping patients like Pete live life to the fullest.

Two research scientist in a lab

Innovation is in our DNA: Learn more about our capabilities.

Swiss employees meeting in a conference room.

We're looking for the best and brightest. Can you see yourself at CSL?

red text logo for CSL Behring

First SCIg Approved for CIDP

HIZENTRA, the First Subcutaneous Immunoglobulin (SCIg) Approved for CIDP

17 Sep 2018 Company
World Haemophilia Day

World Haemophilia Day

CSL Behring Marks World Haemophilia Day by Shipping Bleeding Disorders Medicines to t…

17 Apr 2018 Company
Broadmeadows research scientist

Patient Enrolled in CSL112 Clinical Trial

The AEGIS-II trial will enrol more than 17,000 patients from approximately 1,000 medi…

23 Mar 2018 Company
Forbes Global World's Best Employers Logo

Making Forbes’ Top Global Employers List

Global biotech leader rated at no. 42 for patient focus, innovation and sustainable g…

20 Mar 2018 Company
Aerial view of CSL Berhing Australia Broadmeadows site

New National Fractionation Agreement

CSL Behring today announced that it has signed an agreement with the National Blood A…

11 Dec 2017 Company
CSL Behring Engineering employee infront of Alburx

Expansion of CSL Biotech Facility

CSL today officially opened a new AUD$230 million advanced manufacturing facility at …

07 Dec 2017 Company

Join us and make history with the brightest, most passionate people from every discipline.

Learn More

Innovation spans across our organization with a focus on solving patients' unmet needs.

Learn More
Latest News

Find out what's happening now at CSL Behring.

Learn More